- Home
- SNSE vs NCEL Comparison
SNSE vs NCEL Comparison
Compare SNSE & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNSE | NCEL |
|---|---|---|
| Founded | 2005 | 2008 |
| Country | United States | Switzerland |
| Employees | N/A | 11 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.2M | 10.3M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | SNSE | NCEL |
|---|---|---|
| Price | $33.38 | $2.14 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $65.00 | N/A |
| AVG Volume (30 Days) | ★ 76.3K | 24.0K |
| Earning Date | 05-05-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.26 | $1.83 |
| 52 Week High | $36.76 | $4.70 |
Technical Indicators
Market Signals| Indicator | SNSE | NCEL |
|---|---|---|
| Relative Strength Index (RSI) | 60.91 | 40.91 |
| Support Level | $7.94 | $1.89 |
| Resistance Level | $35.88 | $3.16 |
| Average True Range (ATR) | 3.92 | 0.17 |
| MACD | -0.13 | -0.02 |
| Stochastic Oscillator | 90.51 | 41.55 |
Price Performance
Historical ComparisonAbout SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).
About NCEL NewcelX Ltd. Ordinary Shares
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.